The transgenic mouse model we studied, 3xTg‐AD, harbors three human transgenes (APP, PSEN1, and MAPT) and exhibits both amyloid‐β and tau pathology shown to occur as early as 6 and 12 months, respectively.41 The gene discussed is MAPT; the disease is Alzheimer disease.